Lanzhou Foci Pharmaceutical Co.Ltd(002644) : 2018 annual report (Updated)

Lanzhou Foci Pharmaceutical Co.Ltd(002644)

2018 Annual Report

Updated in March 2022

Section I important tips, contents and definitions

The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee that the contents of the annual report are true, accurate and complete without false records, misleading statements or major omissions, and bear individual and joint legal liabilities.

Shi Aiguo, the person in charge of the company, LV Zhiying, the person in charge of accounting, and Ren Jinfeng, the person in charge of the accounting organization (Accounting Supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in the annual report.

All the reports of the board of directors have been considered.

The profit distribution plan approved by the board of directors is: take 510, 657, 000 shares as the base, distribute cash dividend of 0.13 yuan (including tax) to all shareholders for every 10 shares, send bonus shares of 0 share (including tax), and do not use the accumulation fund to increase the share capital.

The company has risks such as pharmaceutical policy and market, price fluctuation of raw materials, new product research and development, human resources and management. For details, see “section IV discussion and analysis of operation”. Please pay attention to investment risks.

catalogue

Section I important tips, contents and definitions Section 2 company profile and main financial indicators Section III business summary of the company Section IV discussion and analysis of business situation 12 section V important matters Section VI changes in shares and shareholders 37 Section VII preferred shares Section VIII directors, supervisors, senior managers and employees Section 9 corporate governance Section 10 relevant information of corporate bonds 54 section Xi financial report 55 section 12 list of documents for future reference one hundred and forty

interpretation

Explanatory item refers to the explanatory content

Company / the company refers to Lanzhou Foci Pharmaceutical Co.Ltd(002644)

The articles of association refers to Lanzhou Foci Pharmaceutical Co.Ltd(002644) articles of association

Company Law refers to the company law of the people’s Republic of China and its amendments

“Securities Law” refers to the securities law of the people’s Republic of China and its amendments

Reporting period / current reporting period refers to 2018

The initial raised investment project refers to the technical transformation project to expand the production scale of concentrated pills

Lanzhou New Area Lanzhou Foci Pharmaceutical Co.Ltd(002644) science and Technology Industrial Park project, Gansu Fuci natural drug Industrial Park project, non-public offering and investment project refers to the marketing network and information construction project, and the project of Gansu Modern Traditional Chinese medicine preparation engineering technology research center

Lanzhou New Area Project / new area project refers to the project of Lanzhou New Area Lanzhou Foci Pharmaceutical Co.Ltd(002644) science and Technology Industrial Park

The project of natural medicine industrial park refers to the project of Gansu foci natural medicine industrial park

Health industry company refers to Lanzhou Fuci Health Industry Co., Ltd

Chinese herbal medicine management company refers to Gansu foci Chinese Herbal Medicine Management Co., Ltd

Pharmaceutical industry development company refers to Gansu foci Pharmaceutical Industry Development Co., Ltd

Eco agriculture company refers to Gansu foci Eco Agriculture Co., Ltd

LAN Guotou refers to Lanzhou state owned investment (holding) Construction Group Co., Ltd

RMB / 10000 yuan / 100 million yuan refers to RMB / 10000 yuan / 100 million yuan

The new version of GMP refers to the good manufacturing practice (revised in 2010)

The new version of GSP refers to the code for quality management of Pharmaceutical Trading (revised in 2013)

Gap of Chinese medicinal materials refers to the production quality management specification of Chinese medicinal materials

Section II Company Profile and main financial indicators

1、 Company information

Stock abbreviation Lanzhou Foci Pharmaceutical Co.Ltd(002644) stock code Lanzhou Foci Pharmaceutical Co.Ltd(002644)

Changed stock abbreviation (if any) none

Shenzhen Stock Exchange

Chinese name of the company Lanzhou Foci Pharmaceutical Co.Ltd(002644)

Chinese abbreviation of the company Lanzhou Foci Pharmaceutical Co.Ltd(002644)

Foreign language name of the company (if any) Lanzhou foci Pharmaceutical Co., Ltd

The abbreviation of the company’s foreign name (if any) foci pharmaceutical

The legal representative of the company is Shi Aiguo

Registered address: No. 2289, Huashan Road, Lanzhou New Area, Lanzhou City, Gansu Province

Postal code of registered address 730000

Office address: No. 2289, Huashan Road, Lanzhou New Area, Lanzhou City, Gansu Province

Postal code of office address 730000

Company website: www.fczy.com com.

E-mail [email protected].

2、 Contact person and contact information

Secretary of the board of directors and securities affairs representative

Name: LV Zhiying an Wenting

Contact address: No. 2289, Huashan Road, Lanzhou New Area, Lanzhou City, Gansu Province

Tel: 0931825 Hangzhou Pinming Software Co.Ltd(688109) 318362318

Fax: 09318368945

E-mail lvzhiying3619126.com. [email protected].

3、 Information disclosure and preparation location

The names of the information disclosure media selected by the company include China Securities News, Shanghai Securities News, securities daily and securities times

The website of the website designated by the CSRC for publishing the annual report is www.cn info. com. cn.

The company’s annual report is prepared at the Securities Department of the company

4、 Registration changes

Organization Code: 91620 Guangdong Golden Dragon Development Inc(000712) 762468n (Unified Social Credit Code)

Whether the changes of the company’s main business (if any) have changed since its listing

There is no change in the previous changes of controlling shareholders (if any)

5、 Other relevant information: accounting firm employed by the company

Name of accounting firm Ruihua accounting firm (special general partnership)

Office address of the accounting firm: 4th floor, building 2, No. 16 courtyard, Middle West Fourth Ring Road, Haidian District, Beijing

Name of signature accountant: Zhang Haiying, fan Cang

Recommendation agencies hired by the company to perform continuous supervision duties during the reporting period √ applicable □ not applicable

Name of recommendation institution office address of recommendation institution name of recommendation representative during continuous supervision

Southwest Securities Co.Ltd(600369) Zhan Hui and Huang Jia, No. 8, qiaobeiyuan, Jiangbei District, Chongqing, January 2015 to the end of the use of the raised funds of the company

Financial consultant hired by the company to perform continuous supervision duties during the reporting period □ applicable √ not applicable VI. whether the company needs to retroactively adjust or restate the accounting data of previous years for main accounting data and financial indicators □ yes √ no

20182017 year-on-year increase or decrease 2016

Operating income (yuan): 5445810462450113971654 8.67% 36325542048

Net profit attributable to shareholders of the listed company (yuan) 72918229167409278260 – 1.59% 6092623843

Deduction attributable to shareholders of listed companies non recurring

Net profit from profit and loss (yuan) 47486099136397586708 – 23.85% 5590633561

Net cash flow from operating activities (yuan) 36663112056642306238 – 44.80% 5690104493

Basic earnings per share (yuan / share) 0.1428 0.1451 0.28% 0.1193

Diluted earnings per share (yuan / share) 0.1428 0.1451 0.28% 0.1193

Weighted average return on net assets 5.21% – 0.27% 4.83%

Increase or decrease at the end of 2018 and 2017 compared with the end of the previous year at the end of 2016

Total assets (yuan) 252400117854234982516017 7.41% 203671444009

Net assets attributable to shareholders of the listed company (yuan): 144042789080135914820264 5.98% 129058326404

7、 Differences in accounting data under domestic and foreign accounting standards 1. Differences in net profit and net assets in financial reports disclosed in accordance with international accounting standards and Chinese accounting standards □ applicable √ not applicable. There is no difference in net profit and net assets in financial reports disclosed in accordance with international accounting standards and Chinese accounting standards in the reporting period of the company.

2. At the same time, the difference between the net profit and net assets in the financial report disclosed in accordance with the overseas accounting standards and the Chinese accounting standards □ applicable √ not applicable. There is no difference between the net profit and net assets in the financial report disclosed in accordance with the overseas accounting standards and the Chinese accounting standards in the reporting period. 8、 Quarterly main financial indicators

Unit: Yuan

The first

- Advertisment -